Trial Profile

A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 08 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jan 2025 According to an Acadia Pharmaceuticals media release, enrollment of the last patient anticipated in the fourth quarter of 2025, followed by top-line results announcement in the first half of 2026.
30 Nov 2023 According to Acadia Pharmaceuticals media release, Shawn McCandless, MD, Chair, Department of Genetics and Metabolism, Children's Hospital Colorado and investigator of this COMPASS PWS study.
30 Nov 2023 Status changed to recruiting, according to Acadia Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com